Hofbauer LC and Heufelder AE |
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. |
2001 |
Arthritis Rheum. |
pmid:11229454
|
Leach RJ et al. |
The genetics of Paget's disease of the bone. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11231972
|
Hofbauer LC and Heufelder AE |
[Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. |
2001 |
Dtsch. Med. Wochenschr. |
pmid:11233883
|
Bolon B et al. |
Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. |
2001 |
Mol. Ther. |
pmid:11237676
|
Sasaki N et al. |
Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. |
2001 |
Nephrol. Dial. Transplant. |
pmid:11239019
|
Takeuchi T et al. |
Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. |
2001 |
Biochem. Pharmacol. |
pmid:11239501
|
Mori K et al. |
Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. |
2001 |
Cell. Immunol. |
pmid:11243701
|
Michigami T et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. |
2001 |
Cancer Res. |
pmid:11245477
|
Wada N et al. |
Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. |
2001 |
J. Periodont. Res. |
pmid:11246705
|
Lories RJ and Luyten FP |
Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. |
2001 |
Clin. Rheumatol. |
pmid:11254237
|
Chen D et al. |
ELISA methodology for detection of modified osteoprotegerin in clinical studies. |
2001 |
Clin. Chem. |
pmid:11274028
|
Collin-Osdoby P et al. |
Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. |
2001 |
J. Biol. Chem. |
pmid:11274143
|
Mackie PS et al. |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. |
2001 |
Br. J. Cancer |
pmid:11286476
|
Wise GE et al. |
Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. |
2001 |
Clin Anat |
pmid:11301468
|
Brown JM et al. |
Osteoprotegerin and rank ligand expression in prostate cancer. |
2001 |
Urology |
pmid:11306358
|
Fukagawa M et al. |
[PTH and bone metabolism in chronic dialysis patients]. |
2001 |
Rinsho Byori |
pmid:11307321
|
Horowitz MC et al. |
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. |
2001 |
Cytokine Growth Factor Rev. |
pmid:11312114
|
Hofbauer LC et al. |
Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. |
2001 |
J. Rheumatol. |
pmid:11327234
|
Atkins GJ et al. |
Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. |
2001 |
Bone |
pmid:11336917
|
Komine M et al. |
Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. |
2001 |
Bone |
pmid:11344046
|
Lin DL et al. |
Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. |
2001 |
Prostate |
pmid:11351351
|
Sparks AB et al. |
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. |
2001 |
Calcif. Tissue Int. |
pmid:11351498
|
Disthabanchong S and González EA |
Regulation of bone cell development and function: implication for renal osteodystrophy. |
2001 |
J. Investig. Med. |
pmid:11352181
|
Kotake S et al. |
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. |
2001 |
Arthritis Rheum. |
pmid:11352231
|
Saika M et al. |
17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. |
2001 |
Endocrinology |
pmid:11356664
|
Luger NM et al. |
Osteoprotegerin diminishes advanced bone cancer pain. |
2001 |
Cancer Res. |
pmid:11358823
|
Goltzman D |
Osteolysis and cancer. |
2001 |
J. Clin. Invest. |
pmid:11375409
|
Zhang J et al. |
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. |
2001 |
J. Clin. Invest. |
pmid:11375413
|
Kostenuik PJ and Shalhoub V |
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. |
2001 |
Curr. Pharm. Des. |
pmid:11375772
|
Kanzaki H et al. |
Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. |
2001 |
J. Dent. Res. |
pmid:11379890
|
Hein GE |
[Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. |
2001 |
Z Rheumatol |
pmid:11383046
|
Morony S et al. |
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. |
2001 |
Cancer Res. |
pmid:11389072
|
Abu-Amer Y |
IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. |
2001 |
J. Clin. Invest. |
pmid:11390419
|
Kon T et al. |
Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. |
2001 |
J. Bone Miner. Res. |
pmid:11393777
|
Fazzalari NL et al. |
The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. |
2001 |
J. Bone Miner. Res. |
pmid:11393778
|
Kim KJ et al. |
Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. |
2001 |
J. Biomed. Mater. Res. |
pmid:11410897
|
Haynes DR et al. |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. |
2001 |
Rheumatology (Oxford) |
pmid:11426018
|
Szulc P et al. |
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11443182
|
Sakiyama H et al. |
Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. |
2001 |
J. Bone Miner. Metab. |
pmid:11448014
|
Choi Y et al. |
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. |
2001 |
Eur. J. Immunol. |
pmid:11449372
|
Thirunavukkarasu K et al. |
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. |
2001 |
J. Biol. Chem. |
pmid:11451955
|
Seck T et al. |
Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. |
2001 |
Eur. J. Endocrinol. |
pmid:11454517
|
Burguera B et al. |
Leptin reduces ovariectomy-induced bone loss in rats. |
2001 |
Endocrinology |
pmid:11459801
|
Yamagishi T et al. |
Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. |
2001 |
Endocrinology |
pmid:11459812
|
Furuya D et al. |
Immuno-PCR assay for homodimeric osteoprotegerin. |
2001 |
Clin. Chem. |
pmid:11468243
|
Thomas GP et al. |
Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. |
2001 |
J. Endocrinol. |
pmid:11479141
|
Hofbauer LC and Heufelder AE |
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. |
2001 |
J. Mol. Med. |
pmid:11485016
|
Hofbauer LC and Schoppet M |
Osteoprotegerin: a link between osteoporosis and arterial calcification? |
2001 |
Lancet |
pmid:11498208
|
Sakai A et al. |
1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. |
2001 |
J. Bone Miner. Metab. |
pmid:11498729
|
Ikeda T et al. |
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. |
2001 |
J. Bone Miner. Res. |
pmid:11499864
|
Hofbauer LC et al. |
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. |
2001 |
Cancer |
pmid:11505389
|
Ma YL et al. |
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. |
2001 |
Endocrinology |
pmid:11517184
|
Bateman TA et al. |
Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. |
2001 |
J. Orthop. Res. |
pmid:11518255
|
Myoung H et al. |
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. |
2001 |
J. Periodont. Res. |
pmid:11519698
|
Haynes DR et al. |
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. |
2001 |
J Bone Joint Surg Br |
pmid:11521937
|
Marco-Mingot M et al. |
Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. |
2001 |
Clin. Genet. |
pmid:11531977
|
Allan GF et al. |
Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. |
2001 |
Steroids |
pmid:11546554
|
Raffai RL et al. |
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11553788
|
Hocking LJ et al. |
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. |
2001 |
Am. J. Hum. Genet. |
pmid:11555792
|
Pearse RN et al. |
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11562486
|
Kostenuik PJ et al. |
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. |
2001 |
Endocrinology |
pmid:11564687
|
Seidel C et al. |
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. |
2001 |
Blood |
pmid:11568016
|
Yan T et al. |
Regulation of osteoclastogenesis and RANK expression by TGF-beta1. |
2001 Aug 1-9 |
J. Cell. Biochem. |
pmid:11573248
|
Fukagawa M et al. |
Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. |
2001 |
Am. J. Kidney Dis. |
pmid:11576943
|
Sato T et al. |
Osteoprotegerin levels before and after renal transplantation. |
2001 |
Am. J. Kidney Dis. |
pmid:11576949
|
Feuerherm AJ et al. |
Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. |
2001 |
Scand. J. Rheumatol. |
pmid:11578019
|
Quinn JM et al. |
Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. |
2001 |
J. Bone Miner. Res. |
pmid:11585342
|
Choi SJ et al. |
Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. |
2001 |
J. Bone Miner. Res. |
pmid:11585344
|
Miyamoto T et al. |
Bifurcation of osteoclasts and dendritic cells from common progenitors. |
2001 |
Blood |
pmid:11588053
|
Satoh K et al. |
Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. |
2001 |
Pancreas |
pmid:11590320
|
Yano K et al. |
Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11594776
|
Brown JM et al. |
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. |
2001 |
Clin. Cancer Res. |
pmid:11595685
|
Price PA et al. |
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11597934
|
Rosa-Rañal M et al. |
[New paradigms in the regulation of bone metabolism]. |
2001 Jul-Aug |
Rev. Invest. Clin. |
pmid:11599485
|
Kawahara N et al. |
Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. |
2001 |
Chem. Pharm. Bull. |
pmid:11605678
|
Boissy P et al. |
RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11606048
|
Jung K et al. |
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. |
2001 |
Clin. Chem. |
pmid:11673385
|
Lean JM et al. |
FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. |
2001 |
Blood |
pmid:11675341
|
Fiumara P et al. |
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. |
2001 |
Blood |
pmid:11675352
|
Yano K et al. |
Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. |
2001 |
J. Bone Miner. Metab. |
pmid:11685652
|
Chikazu D et al. |
Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. |
2001 |
J. Bone Miner. Res. |
pmid:11697804
|
Khosla S |
Minireview: the OPG/RANKL/RANK system. |
2001 |
Endocrinology |
pmid:11713196
|
Nemec K and Schubert-Zsilavecz M |
[Future therapies for metabolic bone diseases. New concepts and targets]. |
2001 |
Pharm Unserer Zeit |
pmid:11715689
|
Kuntz KA et al. |
An immunohistochemical study of osteoprotegerin in the human dental pulp. |
2001 |
J Endod |
pmid:11716077
|
Hofbauer LC and Schoppet M |
Serum measurement of osteoprotegerin--clinical relevance and potential applications. |
2001 |
Eur. J. Endocrinol. |
pmid:11720890
|
Ueland T et al. |
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. |
2001 |
Eur. J. Endocrinol. |
pmid:11720891
|
Sakai E et al. |
Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. |
2001 |
J. Biochem. |
pmid:11726283
|
Ito S et al. |
Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. |
2002 |
J. Biol. Chem. |
pmid:11733492
|
Lindberg MK et al. |
Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. |
2001 |
J. Endocrinol. |
pmid:11739008
|
Giuliani N et al. |
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. |
2001 |
Blood |
pmid:11739153
|
Croucher PI et al. |
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. |
2001 |
Blood |
pmid:11739154
|
Dhore CR et al. |
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11742876
|
Halladay DL et al. |
Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. |
2001 |
J. Cell. Biochem. |
pmid:11746511
|
Cao Y et al. |
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. |
2001 |
Cell |
pmid:11747812
|
Chung H et al. |
Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. |
2001 |
J. Korean Med. Sci. |
pmid:11748360
|
Komuro H et al. |
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. |
2001 |
Arthritis Rheum. |
pmid:11762937
|
Whyte MP and Hughes AE |
Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. |
2002 |
J. Bone Miner. Res. |
pmid:11771666
|
Yang X et al. |
Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:11779130
|
Nosaka K et al. |
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. |
2002 |
Blood |
pmid:11781248
|
Ramalho AC et al. |
Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. |
2001 |
Cytokine |
pmid:11792122
|